Soren Lehmann

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: LEUKEMIA & LYMPHOMA. 2024;:1-9

Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data

Abe C; Keto J; Lilja M; Konradsen M; Mesterton J; Hoglund M; Lazarevic V; Lehmann S; Juliusson G
Article: NPJ PRECISION ONCOLOGY. 2024;8(1):38

Delineating functional and molecular impact of ex vivo sample handling in precision medicine

Struyf N; Osterroos A; Vesterlund M; Arnroth C; James T; Sunandar S; Mermelekas G; Bohlin A; Hamberg Levedahl K; Bengtzen S; Jafari R; Orre LM; Lehtio J; Lehmann S; Ostling P; Kallioniemi O; Seashore-Ludlow B; Erkers T
Article: NATURE CANCER. 2023;4(10):1474-1490

A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo

Giannakopoulou E; Lehander M; Virding Culleton S; Yang W; Li Y; Karpanen T; Yoshizato T; Rustad EH; Nielsen MM; Bollineni RC; Tran TT; Delic-Sarac M; Gjerdingen TJ; Douvlataniotis K; Laos M; Ali M; Hillen A; Mazzi S; Chin DWL; Mehta A; Holm JS; Bentzen AK; Bill M; Griffioen M; Gedde-Dahl T; Lehmann S; Jacobsen SEW; Woll PS; Olweus J
Article: LEUKEMIA. 2023;37(9):1830-1841

Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells

Palau A; Segerberg F; Lidschreiber M; Lidschreiber K; Naughton AJ; Needhamsen M; Jung LA; Jagodic M; Cramer P; Lehmann S; Carlsten M; Lennartsson A
Article: BLOOD. 2023;142(1):73-89

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Dolinska M; Cai H; Mansson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-SF; Deneberg S; Soederlund S; Jaedersten M; Ungerstedt J; Tobiasson M; Ostman A; Mustjoki S; Stenke L; Le Blanc K; Hellstroem-Lindberg E; Lehmann S; Ekblom M; Olsson-Stroemberg U; Sigvarosson M; Qian H
Article: LEUKEMIA. 2023;37(5):1103-1112

Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective

Berggren DM; Garelius H; Hjelm PW; Nilsson L; Rasmussen B; Weibull CE; Lambe M; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ejerblad E
Article: HAEMATOLOGICA. 2023;108(4):1015-1025

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications

Nilsson C; Linde F; Hulegardh E; Garelius H; Lazarevic V; Antunovic P; Cammenga J; Deneberg S; Eriksson A; Jadersten M; Bjorkvall CK; Mollgard L; Wennstrom L; Olander E; Hoglund M; Juliusson G; Lehmann S
Article: NPJ PRECISION ONCOLOGY. 2023;7(1):32

Prediction model for drug response of acute myeloid leukemia patients

Trac QT; Pawitan Y; Mou T; Erkers T; Ostling P; Bohlin A; Osterroos A; Vesterlund M; Jafari R; Siavelis I; Backvall H; Kiviluoto S; Orre LM; Rantalainen M; Lehtio J; Lehmann S; Kallioniemi O; Vu TN
Article: BLOOD. 2023;141(7):800-805

Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions

Ryland GL; Umeda M; Holmfeldt L; Lehmann S; Herlin MK; Ma J; Khanlari M; Rubnitz JE; Ries RE; Kosasih HJ; Ekert PG; Goh HN; Tiong IS; Grimmond SM; Haferlach C; Day RB; Ley TJ; Meshinchi S; Ma X; Blombery P; Klco JM
Article: JOURNAL OF INTERNAL MEDICINE. 2022;292(6):925-940

Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial

Jadersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzen S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Ostling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Hoglund M; Henter J-I; Herold N
Article: HAEMATOLOGICA. 2022;107(8):1786-1795

A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo

Arruda LCM; Stikvoort A; Lambert M; Jin L; Rivera LS; Alves RMP; de Moura TR; Mim C; Lehmann S; Axelsson-Robertson R; Dick JE; Mattsson J; Onfelt B; Carlsten M; Uhlin M
Article: NATURE COMMUNICATIONS. 2022;13(1):4033

Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays.

Chen L; Eriksson A; Weström S; Pandzic T; Lehmann S; Cavelier L; Landegren U
Article: HAEMATOLOGICA. 2022;107(7):1528-1537

A risk score based on real-world data to predict early death in acute promyelocytic leukemia

Osterroos A; Maia T; Eriksson A; Jadersten M; Lazarevic V; Wennstrom L; Antunovic P; Cammenga J; Deneberg S; Lorenz F; Mollgard L; Uggla B; Olander E; Aguiar E; Trigo F; Hoglund M; Juliusson G; Lehmann S
Article: NATURE BIOTECHNOLOGY. 2022;40(4):488-498

T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes

Ali M; Giannakopoulou E; Li Y; Lehander M; Culleton SV; Yang W; Knetter C; Odabasi MC; Bollineni RC; Yang X; Foldvari Z; Boschen M-L; Taraldsrud E; Stronen E; Toebes M; Hillen A; Mazzi S; de Ru AH; Janssen GMC; Kolstad A; Tjonnfjord GE; Lie BA; Griffioen M; Lehmann S; Osnes LT; Buechner J; Garcia KC; Schumacher TN; van Veelen PA; Leisegang M; Jacobsen SEW; Woll P; Olweus J
Article: CANCER RESEARCH COMMUNICATIONS. 2022;2(3):182-201

MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner

Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickstrom M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson L-G
Article: CANCER RESEARCH. 2021;81(22):5733-5744

MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia

Sanjiv K; Calderon-Montano JM; Pham TM; Erkers T; Tsuber V; Almlof I; Hoglund A; Heshmati Y; Seashore-Ludlow B; Danda AN; Gad H; Wiita E; Gokturk C; Rasti A; Friedrich S; Centio A; Estruch M; Vatsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Monch K; Garnett MJ; Ostling P; Walfridsson J; Helleday T; Berglund UW
Article: HAEMATOLOGICA. 2021;106(10):2566-2577

Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells

Hultmark S; Baudet A; Schmiderer L; Prabhala P; Palma-Tortosa S; Sanden C; Fioretos T; Sasidharan R; Larsson C; Lehmann S; Juliusson G; Ek F; Magnusson M
Article: LEUKEMIA & LYMPHOMA. 2021;62(8):1973-1981

Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study

Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf A; Deneberg S; Jadersten M; Antunovic P; Cammenga J; Mollgard L; Wennstrom L; Olander E; Ehinger M; Fogelstrand L; Hoglund M; Lazarevic VL
Article: GENES CHROMOSOMES & CANCER. 2021;60(6):426-433

Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study

Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Hoglund M; Lehmann S; Derolf A; Deneberg S; Antunovic P; Cammenga J; Mollgard L; Wennstrom L; Lilljebjorn H; Rissler M; Fioretos T; Lazarevic VL
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(5):580-588

The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia

Mou T; Pawitan Y; Stahl M; Vesterlund M; Deng W; Jafari R; Bohlin A; Osterroos A; Siavelis L; Backvall H; Erkers T; Kiviluoto S; Seashore-Ludlow B; Ostling P; Orre LM; Kallioniemi O; Lehmann S; Lehtio J; Trung NV
Article: BLOOD ADVANCES. 2021;5(4):1003-1016

Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML

Mareschal S; Palau A; Lindberg J; Ruminy P; Nilsson C; Bengtzen S; Engvall M; Eriksson A; Neddermeyer A; Marchand V; Jansson M; Bjorklund M; Jardin F; Rantalainen M; Lennartsson A; Cavelier L; Gronberg H; Lehmann S
Article: NATURE COMMUNICATIONS. 2021;12(1):1054

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML

Mer AS; Heath EM; Tonekaboni SAM; Dogan-Artun N; Nair SK; Murison A; Garcia-Prat L; Shlush L; Hurren R; Voisin V; Bader GD; Nislow C; Rantalainen M; Lehmann S; Gower M; Guidos CJ; Lupien M; Dick JE; Minden MD; Schimmer AD; Haibe-Kains B
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):474-483

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study

Berggren DM; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ungerstedt J; Ejerblad E
Article: BLOOD. 2020;136(3):339-352

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding

Mujahed H; Miliara S; Neddermeyer A; Bengtzen S; Nilsson C; Deneberg S; Cordeddu L; Ekwall K; Lennartsson A; Lehmann S
Article: CLINICAL CANCER RESEARCH. 2020;26(14):3597-3607

RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia

Anande G; Deshpande NP; Mareschal S; Batcha AMN; Hampton HR; Herold T; Lehmann S; Wilkins MR; Wong JWH; Unnikrishnan A; Pimanda JE
Article: GENOME BIOLOGY. 2020;21(1):153

Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs

Do C; Dumont ELP; Salas M; Castano A; Mujahed H; Maldonado L; Singh A; DaSilva-Arnold SC; Bhagat G; Lehman S; Christiano AM; Madhavan S; Nagy PL; Green PHR; Feinman R; Trimble C; Illsley NP; Marder K; Honig L; Monk C; Goy A; Chow K; Goldlust S; Kaptain G; Siegel D; Tycko B
Article: BLOOD CANCER JOURNAL. 2020;10(6):67

Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia

Osterroos A; Bjorklund M; Eriksson A; Lindberg J; Nilsson C; Mareschal S; Rantalainen M; Gronberg H; Lehmann S
Article: BLOOD ADVANCES. 2020;4(6):1094-1101

The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Juliusson G; Jadersten M; Deneberg S; Lehmann S; Mollgard L; Wennstrom L; Antunovic P; Cammenga J; Lorenz F; Olander E; Lazarevic VL; Hoglund M
Article: EMBO MOLECULAR MEDICINE. 2020;12(3):e10419

Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy

Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CBJ; Sandhow L; Kutzner J; Myrberg IH; Bunten SS; Axelsson H; Zhang SM; Rasti A; Makela P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtio J; Rassidakis GZ; Tamm KP; Warpman-Berglund U; Heyman M; Grander D; Lehmann S; Lundback T; Qian H; Henter J-I; Schaller T; Helleday T; Herold N
Article: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(29):2632-2642

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas P-Y; Dombret H; Preudhomme C; Micol J-B; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch J-H; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(9):1770-1778

Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting

Nilsson C; Hulegardh E; Garelius H; Mollgard L; Brune M; Wahlin A; Lenhoff S; Frodin U; Remberger M; Hoglund M; Juliusson G; Stockelberg D; Lehmann S
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(10):1094-1101

Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia

Wang M; Lindberg J; Klevebring D; Nilsson C; Lehmann S; Gronberg H; Rantalainen M
Article: SCIENTIFIC REPORTS. 2018;8(1):11293

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia

Hornung R; Jurinovic V; Batcha AMN; Bamopoulos SA; Rothenberg-Thurley M; Amler S; Sauerlands MC; Berdel WE; Woermann BJ; Bohlander SK; Braess J; Hiddemann W; Lehmann S; Mareschal S; Spiekermann K; Metzeler KH; Herold T; Boulesteix A-L
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;181(5):614-627

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register

Berggren DM; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ejerblad E
Article: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2018;11(1):52

Expression levels of long non-coding RNAs are prognostic for AML outcome

Mer AS; Lindberg J; Nilsson C; Klevebring D; Wang M; Gronberg H; Lehmann S; Rantalainen M
Article: FREE RADICAL BIOLOGY AND MEDICINE. 2018;117:247-257

Selenite and methylseleninic acid epigenetically affects distinct gene sets in myeloid leukemia: A genome wide epigenetic analysis

Khalkar P; Ali HA; Codo P; Diaz Argelich N; Martikainen A; Arzenani MK; Lehmann S; Walfridsson J; Ungerstedt J; Fernandes AP
Article: LEUKEMIA. 2017;31(10):2029-2036

Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling

Wang M; Lindberg J; Klevebring D; Nilsson C; Mer AS; Rantalainen M; Lehmann S; Gronberg H
Article: CANCER IMMUNOLOGY RESEARCH. 2017;5(8):654-665

Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells

Liu LL; Beziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellstrom-Lindberg E; Soderhall S; Heyman M; Grander D; Malmberg K-J
Article: LEUKEMIA. 2017;31(5):1108-1116

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Ilander M; Olsson-Stromberg U; Schlums H; Guilhot J; Bruck O; Lahteenmaki H; Kasanen T; Koskenvesa P; Soderlund S; Hoglund M; Markevarn B; Sjalander A; Lotfi K; Dreimane A; Lubking A; Holm E; Bjoreman M; Lehmann S; Stenke L; Ohm L; Gedde-Dahl T; Majeed W; Ehrencrona H; Koskela S; Saussele S; Mahon F-X; Porkka K; Hjorth-Hansen H; Bryceson YT; Richter J; Mustjoki S
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(5):493-500

Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry

Lazarevic VL; Rosso A; Juliusson G; Antunovic P; Derolf AR; Deneberg S; Mollgard L; Uggla B; Wennstrom L; Wahlin A; Hoglund M; Lehmann S; Johansson B
Article: ONCOTARGET. 2017;8(17):28812-28825

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease

Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grovdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellstrom-Lindberg E; Ungerstedt J
Article: BLOOD. 2017;129(7):e13-e25

Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia

Qu Y; Siggens L; Cordeddu L; Gaidzik VI; Karlsson K; Bullinger L; Doehner K; Ekwall K; Lehmann S; Lennartsson A
Article: NATURE MEDICINE. 2017;23(2):256-263

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies

Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CBJ; Heshmati Y; Hagenkort A; Kutzner J; Paget BDG; Calderon-Montano JM; Loseva O; Jemth A-S; Bulli L; Axelsson H; Tesi B; Valerie NCK; Hoglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grander D; Lundback T; Kogner P; Henter J-I; Helleday T; Schaller T
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2016;174(1):117-126

Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells

Ali D; Mohammad DK; Mujahed H; Jonson-Videsater K; Nore B; Paul C; Lehmann S
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2015;90(9):800-805

Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia

Lazarevic V; Rosso A; Juliusson G; Antunovic P; Rangert-Derolf A; Lehmann S; Mollgard L; Uggla B; Wennstrom L; Wahlin A; Hoglund M; Johansson B
Article: EXPERIMENTAL HEMATOLOGY. 2015;43(8):609-624

Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis

Eriksson A; Lennartsson A; Lehmann S
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2015;94(5):419-423

Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia

Lazarevic V; Horstedt A-S; Johansson B; Antunovic P; Billstrom R; Derolf A; Lehmann S; Moellgard L; Peterson S; Stockelberg D; Uggla B; Vennstroem L; Wahlin A; Hoeglund M; Juliusson G
Article: LEUKEMIA. 2015;29(5):1084-1091

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

Lengfelder E; Lo-Coco F; Ades L; Montesinos P; Grimwade D; Kishore B; Ramadan SM; Pagoni M; Breccia M; Huerta AJG; Nloga AM; Gonzalez-Sanmiguel JD; Schmidt A; Lambert J-F; Lehmann S; Di Bona E; Cassinat B; Hofmann W-K; Gorlich D; Sauerland M-C; Fenaux P; Sanz M
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2015;90(3):208-214

Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry

Hulegardh E; Nilsson C; Lazarevic V; Garelius H; Antunovic P; Rangert Derolf A; Mollgard L; Uggla B; Wennstrom L; Wahlin A; Hoglund M; Juliusson G; Stockelberg D; Lehmann S
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(26):2477-2487

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

Genovese G; Kaehler AK; Handsaker RE; Lindberg J; Rose SA; Bakhoum SF; Chambert K; Mick E; Neale BM; Fromer M; Purcell SM; Svantesson O; Landen M; Hoeglund M; Lehmann S; Gabriel SB; Moran JL; Lander ES; Sullivan PF; Sklar P; Groenberg H; Hultman CM; McCarroll SA
Article: EPIGENETICS. 2014;9(8):1108-1119

Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes

Qu Y; Lennartsson A; Gaidzik VI; Deneberg S; Karimi M; Bengtzen S; Hoglund M; Bullinger L; Doehner K; Lehmann S
Article: BMC GENOMICS. 2014;15(1):487

Relationship between genome and epigenome - challenges and requirements for future research

Almouzni G; Altucci L; Amati B; Ashley N; Baulcombe D; Beaujean N; Bock C; Bongcam-Rudloff E; Bousquet J; Braun S; Bressac-de Paillerets B; Bussemakers M; Clarke L; Conesa A; Estivill X; Fazeli A; Grgurevic N; Gut I; Heijmans BT; Hermouet S; Houwing-Duistermaat J; Iacobucci I; Ilas J; Kandimalla R; Krauss-Etschmann S; Lasko P; Lehmann S; Lindroth A; Majdic G; Marcotte E; Martinelli G; Martinet N; Meyer E; Miceli C; Mills K; Moreno-Villanueva M; Morvan G; Nickel D; Niesler B; Nowacki M; Nowak J; Ossowski S; Pelizzola M; Pochet R; Potocnik U; Radwanska M; Raes J; Rattray M; Robinson MD; Roelen B; Sauer S; Schinzer D; Slagboom E; Spector T; Stunnenberg HG; Tiligada E; Torres-Padilla M-E; Tsonaka R; Van Soom A; Vidakovic M; Widschwendter M
Article: EPIGENETICS. 2014;9(6):910-917

microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia

Deneberg S; Kanduri M; Ali D; Bengtzen S; Karimi M; Qu Y; Kimby E; Mansouri L; Rosenquist R; Lennartsson A; Lehmann S
Article: BLOOD. 2014;123(17):e79-e89

Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation

Ronnerblad M; Andersson R; Olofsson T; Douagi I; Karimi M; Lehmann S; Hoof I; de Hoon M; Itoh M; Nagao-Sato S; Kawaji H; Lassmann T; Carninci P; Hayashizaki Y; Forrest ARR; Sandelin A; Ekwall K; Arner E; Lennartsson A
Article: BLOOD CANCER JOURNAL. 2014;4(2):e188

Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience

Lazarevic V; Horstedt A-S; Johansson B; Antunovic P; Billstrom R; Derolf A; Hulegardh E; Lehmann S; Mollgard L; Nilsson C; Peterson S; Stockelberg D; Uggla B; Wennstrom L; Wahlin A; Hoglund M; Juliusson G
Article: BLOOD. 2013;122(7):1284-1292

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Hoglund M; Sandin F; Hellstrom K; Bjoreman M; Bjorkholm M; Brune M; Dreimane A; Ekblom M; Lehmann S; Ljungman P; Malm C; Markevarn B; Myhr-Eriksson K; Ohm L; Olsson-Stromberg U; Sjalander A; Wadenvik H; Simonsson B; Stenke L; Richter J
Article: LEUKEMIA & LYMPHOMA. 2013;54(4):843-850

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies

Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grander D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Osterborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(29):3633-3639

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann S; Bykov VJN; Ali D; Andren O; Cherif H; Tidefelt U; Uggla B; Yachnin J; Juliusson G; Moshfegh A; Paul C; Wiman KG; Andersson P-O
Article: HAEMATOLOGICA. 2012;97(9):1380-1388

A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies

Gronbaek K; Mueller-Tidow C; Perini G; Lehmann S; Treppendahl MB; Mills K; Plass C; Schlegelberger B
Article: BLOOD. 2011;118(20):5573-5582

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks

Deneberg S; Guardiola P; Lennartsson A; Qu Y; Gaidzik V; Blanchet O; Karimi M; Bengtzen S; Nahi H; Uggla B; Tidefelt U; Hoglund M; Paul C; Ekwall K; Doehner K; Lehmann S
Article: CANCER. 2011;117(18):4238-4246

Hematopoietic Stem Cell Transplantation Rates and Long-Term Survival in Acute Myeloid and Lymphoblastic Leukemia Real-World Population-Based Data From the Swedish Acute Leukemia Registry 1997-2006

Juliusson G; Karlsson K; Lazarevic VL; Wahlin A; Brune M; Antunovic P; Derolf A; Hagglund H; Karbach H; Lehmann S; Mollgard L; Stockelberg D; Hallbook H; Hoglund M
Article: LEUKEMIA. 2011;25(7):1128-1134

Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry

Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Mollgard L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennstrom L; Hoglund M; Juliusson G
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;86(3):206-215

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

Ali D; Jonsson-Videsater K; Deneberg S; Bengtzen S; Nahi H; Paul C; Lehmann S
Article: LEUKEMIA. 2010;24(5):932-941

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia

Deneberg S; Grovdal M; Karimi M; Jansson M; Nahi H; Corbacioglu A; Gaidzik V; Doehner K; Paul C; Ekstrom TJ; Hellstrom-Lindberg E; Lehmann S
Article: CANCER LETTERS. 2009;282(1):116-123

Selenite is a potent cytotoxic agent for human primary AML cells

Olm E; Jonsson-Videsater K; Ribera-Cortada I; Fernandes AP; Eriksson LC; Lehmann S; Rundlof A-K; Paul C; Bjornstedt M
Article: HAEMATOLOGICA. 2009;94(9):1301-1306

Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells

Akagi T; Shih L-Y; Ogawa S; Gerss J; Moore SR; Schreck R; Kawamata N; Liang D-C; Sanada M; Nannya Y; Deneberg S; Zachariadis V; Nordgren A; Song JH; Dugas M; Lehmann S; Koeffler HP
Article: BLOOD. 2009;113(18):4179-4187

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

Juliusson G; Antunovic P; Derolf A; Lehmann S; Mollgard L; Stockelberg D; Tidefelt U; Wahlin A; Hoglund M
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2008;62(3):439-448

The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia

Mollgard L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsater K; Fioretos T; Andersson A; Paul C; Lehmann S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;141(4):445-453

Mutated and non-mutated TP53 as targets in the treatment of leukaemia

Nahi H; Selivanova G; Lehmann S; Mollgard L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Article: CANCER. 2008;112(6):1296-1305

Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia

Lehmann S; Ogawa S; Raynaud SD; Sanada M; Nannya Y; Ticchioni M; Bastard C; Kawamata N; Koeffler HP
Article: LEUKEMIA & LYMPHOMA. 2008;49(3):508-516

Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia

Nahi H; Lehmann S
Article: THERAPEUTIC DRUG MONITORING. 2007;29(5):626-631

Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia

Lofgren C; Lehmann S; Jonsson-Videsater K; Mollgard L; Linder O; Tidefelt U; Hassan M; Paul C
Article: LEUKEMIA. 2007;21(9):1931-1936

Common deleted genes in the 5q-syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice

Lehmann S; O'Kelly J; Raynaud S; Funk SE; Sage EH; Koeffler HP
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;132(2):230-236

PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion

Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Article: NATURE MEDICINE. 2005;11(6):630-637

Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia

Castor A; Nilsson L; Åstrand-Grundström I; Buitenhuis M; Ramirez C; Anderson K; Strömbeck B; Garwicz S; Békássy AN; Schmiegelow K; Lausen B; Hokland P; Lehmann S; Juliusson G; Johansson B; Jacobsen SEW
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;127(3):285-291

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion

Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
Article: BIOCHEMICAL PHARMACOLOGY. 2002;63(10):1875-1884

Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity -: Effects on thioredoxin reductase and glutathione reductase

Björkhem-Bergman L; Jönsson K; Eriksson LC; Olsson JM; Lehmann S; Paul C; Björnstedt M
Article: LEUKEMIA & LYMPHOMA. 2002;43(4):851-858

The expression of cellular retinoid binding proteins in non-APL leukemic cells and its association with retinoid sensitivity

Lehmann S; Paul C; Törmä H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2001;66(6):357-364

Effects of arsenic trioxide (As₂O₃) on leukemic cells from patients with non-M3 acute myelogenous leukemia:: studies of cytotoxicity, apoptosis and the pattern of resistance

Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Article: BONE MARROW TRANSPLANTATION. 2000;26(2):187-192

Cardiac systolic function before and after hematopoietic stem cell transplantation

Lehmann S; Isberg B; Ljungman P; Paul C
Article: BONE MARROW TRANSPLANTATION. 2000;25(9):993-996

N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation

Ringdén O; Remberger M; Lehmann S; Hentschke P; Mattsson J; Klaesson S; Aschan J
Article: LEUKEMIA RESEARCH. 2000;24(1):19-25

Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML

Lehmann S; Bengtzen S; Broberg U; Paul C
Visa fler

Alla övriga publikationer

Letter: LEUKEMIA. 2024;38(3):663-666

The exon-junction complex helicase eIF4A3 holds therapeutic potential in acute myeloid leukemia

Miliara S; Cozzi E; Zhong X; Chan I; Ekwall K; Lehmann S; Lennartsson A; Bartek J; Kanellis DC
Letter: BLOOD ADVANCES. 2021;5(3):787-790

Impact of treatment delay in acute myeloid leukemia revisited.

Juliusson G; Hagberg O; Lazarevic VL; Lehmann S; Höglund M
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(1):e13-e16

Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years

Osterroos A; Eriksson A; Antunovic P; Cammenga J; Deneberg S; Lazarevic V; Lorenz F; Mollgard L; Derolf AR; Uggla B; Wennstrom L; Olander E; Hoglund M; Juliusson G; Lehmann S
Editorial comment: HAEMATOLOGICA. 2020;105(2):249-251

Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people

Juliusson G; Hoglund M; Lehmann S
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;188(1):187-191

Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor

Derolf A; Juliusson G; Benson L; Floisand Y; Lazarevic V; Antunovic P; Mollgard L; Lehmann S; Uggla B; Wahlin A; Hoglund M; Deneberg S
Letter: BLOOD. 2019;134(18):1558-1561

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period

Juliusson G; Hagberg O; Lazarevic VL; Olander E; Antunovic P; Cammenga J; Wennstrom L; Mollgard L; Brune M; Jadersten M; Deneberg S; Lehmann S; Derolf AR; Hoglund M
Letter: LEUKEMIA. 2017;31(6):1457-1459

Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013

Lehmann S; Deneberg S; Antunovic P; Rangert-Derolf A; Garelius H; Lazarevic V; Myhr-Eriksson K; Mollgard L; Uggla B; Wahlin A; Wennstrom L; Hoglund M; Juliusson G
Letter: LEUKEMIA. 2017;31(3):728-731

Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden

Juliusson G; Abrahamsson J; Lazarevic V; Antunovic P; Derolf A; Garelius H; Lehmann S; Myhr-Eriksson K; Mollgard L; Uggla B; Wahlin A; Wennstrom L; Hoglund M
Letter: BLOOD CANCER JOURNAL. 2016;6(7):e447

An open-label phase I dose-finding study of APR-246 in hematological malignancies

Deneberg S; Cherif H; Lazarevic V; Andersson P-O; von Euler M; Juliusson G; Lehmann S
Letter: HAEMATOLOGICA. 2015;100(6):e223-e225

High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia

Karimi M; Nilsson C; Dimitriou M; Jansson M; Matsson H; Unneberg P; Lehmann S; Kere J; Hellstrom-Lindberg E
Review: ALLERGY. 2008;63(7):842-853

Important research questions in allergy and related diseases:: nonallergic rhinitis:: a GA²LEN paper

Bousquet J; Fokkens W; Burney P; Durham SR; Bachert C; Akdis CA; Canonica GW; Dahlen S-E; Zuberbier T; Bieber T; Bonini S; Bousquet PJ; Brozek JL; Cardell L-O; Crameri R; Custovic A; Demoly P; van Wijk RG; Gjomarkaj M; Holland C; Howarth P; Humbert M; Johnston SL; Kauffmann F; Kowalski ML; Lambrecht B; Lehmann S; Leynaert B; Lodrup-Carlsen K; Mullol J; Niggemann B; Nizankowska-Mogilnicka E; Papadopoulos N; Passalacqua G; Schuenemann HJ; Simon H-U; Todo-Bom A; Toskala E; Valenta R; Wickman M; Zock JP
Meeting abstract: BLOOD. 2007;110(11):161B

Factors affecting long-term survival in non-transplanted acute myeloid leukemia patients

Lof AH; Lehmann S
Meeting abstract: BLOOD. 2007;110(11):133B

Expression of p14ARF in de novo AML with normal karyotype.: Implication on drug resistance and survival

Paul EO; Deneberg S; Lehmann S; Bengtzen S; Nahi H
Meeting abstract: BLOOD. 2004;104(11):501A

Effects of the FLT3 inhibitor PKC 412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.

Möllgård L; Bengtzen S; Fioretos T; Andersson A; Paul C; Lehmann S
Review: LAKARTIDNINGEN. 2004;101(4):282-287

[Drug distribution, resistance to cytostatics and disease pathogenesis: many roles of ABC proteins].

Lehmann S; Rane A
Thesis / dissertation: 2002

In vitro studies of retinoids and arsenic in non-M3 acute myeloid leukemia

Lehmann, Sören
Corrigendum: BIOCHEMICAL PHARMACOLOGY. 2002;64(1):159

Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity -: Effects on thioredoxin reductase and glutathione reductase (vol 63, pg 1875, 2002)

Björkhem-Bergman L; Jönsson K; Eriksson LC; Olsson JM; Lehmann S; Paul C; Björnstedt M
Published conference paper: CLINICAL CANCER RESEARCH. 2001;7(2):367-373

Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells

Lehmann S; Paul C; Törmä H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2000;108(1):198-199

The retinoic acid syndrome in non-M3 acute myeloid leukaemia: A case report

Lehmann S; Paul C
Review: LAKARTIDNINGEN. 1999;96(50):5626-5628

[Arsenic efficient in acute promyelocytic leukemia].

Lehmann S; Paul C

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, Inriktning: hematologi, Karolinska Institutet, 2010
MEDICINE DOKTORSEXAMEN, Institutionen för medicin, Huddinge, Karolinska Institutet, 2002
Läkarexamen, Karolinska Institutet, 1992

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI